Cybin Inc., a clinical-stage biopharmaceutical company, announced on January 8, 2024, the positive results from its Phase 1 studies of proprietary deuterated DMT molecules, CYB004 and SPL028. The studies, conducted on healthy volunteers, showed promising safety, pharmacokinetic (PK), and pharmacodynamic (PD) data, suggesting potential for these compounds in treating generalized anxiety disorder (GAD). CYB004, administered intravenously (IV), and SPL028, administered both IV and intramuscularly (IM), were well-tolerated with no serious adverse events. The IM administration of SPL028 produced robust, short-duration psychedelic effects, indicating a more convenient and patient-friendly dosing method. These results support the progression to a Phase 2 study in GAD, planned for Q1 2024. Cybin's patent portfolio includes 40 granted patents and over 170 pending applications, with 25 patents directly related to the deuterated DMT program. The company's CEO, Doug Drysdale, highlighted the significance of these first-in-human studies and the potential for IM dosing to inform future clinical trials. Cybin is focused on developing psychedelic-based treatments for mental health conditions and is also advancing CYB003, a deuterated psilocybin analog for major depressive disorder.

Cybin Inc., a clinical-stage biopharmaceutical company, announced on January 8, 2024, the positive results from its Phase 1 studies of proprietary deuterated DMT molecules, CYB004 and SPL028. The studies, conducted on healthy volunteers, showed promising safety, pharmacokinetic (PK), and pharmacodynamic (PD) data, suggesting potential for these compounds in treating generalized anxiety disorder (GAD). CYB004, administered intravenously (IV), and SPL028, administered both IV and intramuscularly (IM), were well-tolerated with no serious adverse events. The IM administration of SPL028 produced robust, short-duration psychedelic effects, indicating a more convenient and patient-friendly dosing method. These results support the progression to a Phase 2 study in GAD, planned for Q1 2024. Cybin's patent portfolio includes 40 granted patents and over 170 pending applications, with 25 patents directly related to the deuterated DMT program. The company's CEO, Doug Drysdale, highlighted the significance of these first-in-human studies and the potential for IM dosing to inform future clinical trials. Cybin is focused on developing psychedelic-based treatments for mental health conditions and is also advancing CYB003, a deuterated psilocybin analog for major depressive disorder.